Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

The effects of topiroxostat on vascular function in patients with hyperuricemia.

Higa S, Shima D, Tomitani N, Fujimoto Y, Kario K.

J Clin Hypertens (Greenwich). 2019 Sep 26. doi: 10.1111/jch.13707. [Epub ahead of print]

2.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2019 May;11(5). pii: e10666. doi: 10.15252/emmm.201910666. No abstract available.

3.

Sensitization to Api m 1, Api m 2, and Api m 4 in Japanese beekeepers who had experienced systemic reactions to honeybee stings.

Hirata H, Sato K, Ogasawara T, Funakoshi T, Shima D, Tatewaki M, Shiromori S, Souma R, Satoh H, Sugiyama K, Arima M, Kurasawa K, Fukuda T, Fukushima Y.

Allergol Int. 2019 Apr;68(2):261-263. doi: 10.1016/j.alit.2018.08.008. Epub 2018 Sep 29. No abstract available.

4.

BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changes.

Lee VK, Hosking BM, Holeniewska J, Kubala EC, Lundh von Leithner P, Gardner PJ, Foxton RH, Shima DT.

Diabetologia. 2018 Nov;61(11):2422-2432. doi: 10.1007/s00125-018-4696-x. Epub 2018 Aug 9.

5.

Non-Occlusive Retinal Vascular Inflammation and Role of Red Blood Cell Deformability in Birdshot Chorioretinopathy.

Agrawal R, Ang B, Balne PK, Richards C, Smart T, Cardoso J, Shima D, Jones PH, Pavesio C.

Ocul Immunol Inflamm. 2019;27(6):978-986. doi: 10.1080/09273948.2018.1485959. Epub 2018 Jul 9.

PMID:
29985708
6.

Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review.

Nakata K, Hanai T, Take Y, Osada T, Tsuchiya T, Shima D, Fujimoto Y.

Osteoarthritis Cartilage. 2018 Oct;26(10):1263-1273. doi: 10.1016/j.joca.2018.05.021. Epub 2018 Jun 8. Review.

7.

Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease.

Koide H, Tsujimoto M, Katsube Y, Ochiai M, Hojo A, Furukubo T, Izumi S, Yamakawa T, Shima D, Minegaki T, Nishiguchi K.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1121-1128. doi: 10.1007/s00280-018-3583-y. Epub 2018 Apr 24.

PMID:
29693202
8.

Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality.

Kim IK, Kim K, Lee E, Oh DS, Park CS, Park S, Yang JM, Kim JH, Kim HS, Shima DT, Kim JH, Hong SH, Cho YH, Kim YH, Park JB, Koh GY, Ju YS, Lee HK, Lee S, Kim I.

J Exp Med. 2018 Mar 5;215(3):963-983. doi: 10.1084/jem.20170123. Epub 2018 Feb 14.

9.

High-performance liquid chromatography mass spectrometry of gold and alloy clusters protected by hydrophilic thiolates.

Niihori Y, Shima D, Yoshida K, Hamada K, Nair LV, Hossain S, Kurashige W, Negishi Y.

Nanoscale. 2018 Jan 25;10(4):1641-1649. doi: 10.1039/c7nr07840d.

PMID:
29192295
10.

A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration.

Feng L, Ju M, Lee KYV, Mackey A, Evangelista M, Iwata D, Adamson P, Lashkari K, Foxton R, Shima D, Ng YS.

Am J Pathol. 2017 Oct;187(10):2208-2221. doi: 10.1016/j.ajpath.2017.06.015. Epub 2017 Jul 21.

11.

Survey on the proper use of an adrenaline auto-injector in 551 Japanese outdoor workers after Hymenoptera stings.

Hirata H, Yoshida N, Tatewaki M, Shiromori S, Sato K, Wakayama T, Tokita S, Sugiyama K, Arima M, Kurasawa K, Fukuda T, Shima D, Fukushima Y.

Allergol Int. 2018 Jan;67(1):153-155. doi: 10.1016/j.alit.2017.06.009. Epub 2017 Jul 8. No abstract available.

12.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. No abstract available.

13.

Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.

Katsube Y, Tsujimoto M, Koide H, Ochiai M, Hojyo A, Ogawa K, Kambara K, Torii N, Shima D, Furukubo T, Izumi S, Yamakawa T, Minegaki T, Nishiguchi K.

Cancer Chemother Pharmacol. 2017 Apr;79(4):783-789. doi: 10.1007/s00280-017-3276-y. Epub 2017 Mar 17.

PMID:
28314987
14.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. Erratum in: EMBO Mol Med. 2019 May;11(5):.

15.

Specific IgE sensitization to honey bee venom and auto-injector adrenaline prescriptions for Japanese beekeepers.

Hirata H, Tatewaki M, Shiromori S, Ikeno Y, Akutsu I, Sugiyama K, Arima M, Kurasawa K, Fukuda T, Shima D, Fukushima Y.

Allergol Int. 2017 Jan;66(1):149-151. doi: 10.1016/j.alit.2016.07.001. Epub 2016 Aug 8. No abstract available.

16.

Prescription of adrenaline auto-injectors to 1145 Japanese outdoor workers in 2015.

Tatewaki M, Hirata H, Ikeno Y, Akutsu I, Sekiguchi S, Suzuki N, Sugiyama K, Arima M, Kurasawa K, Fukuda T, Shima D, Fukushima Y.

Allergol Int. 2016 Oct;65(4):483-486. doi: 10.1016/j.alit.2016.04.005. Epub 2016 May 17. No abstract available.

17.

Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism.

Foxton R, Osborne A, Martin KR, Ng YS, Shima DT.

Cell Death Dis. 2016 May 5;7:e2212. doi: 10.1038/cddis.2016.110.

18.

Assessment of red blood cell deformability in type 2 diabetes mellitus and diabetic retinopathy by dual optical tweezers stretching technique.

Agrawal R, Smart T, Nobre-Cardoso J, Richards C, Bhatnagar R, Tufail A, Shima D, H Jones P, Pavesio C.

Sci Rep. 2016 Mar 15;6:15873. doi: 10.1038/srep15873.

19.

Red blood cells in retinal vascular disorders.

Agrawal R, Sherwood J, Chhablani J, Ricchariya A, Kim S, Jones PH, Balabani S, Shima D.

Blood Cells Mol Dis. 2016 Jan;56(1):53-61. doi: 10.1016/j.bcmd.2015.10.003. Epub 2015 Oct 26. Review.

20.

Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.

Nagai N, Ju M, Izumi-Nagai K, Robbie SJ, Bainbridge JW, Gale DC, Pierre E, Krauss AH, Adamson P, Shima DT, Ng YS.

Am J Pathol. 2015 Sep;185(9):2534-49. doi: 10.1016/j.ajpath.2015.04.029. Epub 2015 Jul 16.

21.

Low titer of antibody against Toxoplasma gondii may be related to resistant to cancer.

Seyedeh MS, Nahid S, Nahid M, Shima DP, Morteza Y, Hossein YD.

J Cancer Res Ther. 2015 Apr-Jun;11(2):305-7. doi: 10.4103/0973-1482.144638.

22.

Experimental glaucoma induced by ocular injection of magnetic microspheres.

Bunker S, Holeniewska J, Vijay S, Dahlmann-Noor A, Khaw P, Ng YS, Shima D, Foxton R.

J Vis Exp. 2015 Feb 2;(96). doi: 10.3791/52400.

23.

A Retrospective, Longitudinal Study to Investigate the Change of LDL-C Level and Pharmaceutical Intervention by Using Japanese Health Care Checkup Database.

Tomita C, Ii Y, Shima D, Yamamoto Y, Nagayasu S, Suga O, Fujimoto Y.

Value Health. 2014 Nov;17(7):A765. doi: 10.1016/j.jval.2014.08.282. Epub 2014 Oct 26. No abstract available.

24.

A Database Study to Investigate the Incidence of Anaphylaxis and the Prescription Rate of Self-Injection Epinephrine in Japan.

Shima D, Ii Y, Yamamoto Y, Nagayasu S, Fujimoto Y.

Value Health. 2014 Nov;17(7):A589-90. doi: 10.1016/j.jval.2014.08.2018. Epub 2014 Oct 26. No abstract available.

25.

A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan.

Shima D, Ii Y, Yamamoto Y, Nagayasu S, Ikeda Y, Fujimoto Y.

BMC Cardiovasc Disord. 2014 Sep 17;14:120. doi: 10.1186/1471-2261-14-120.

26.

Differential apicobasal VEGF signaling at vascular blood-neural barriers.

Hudson N, Powner MB, Sarker MH, Burgoyne T, Campbell M, Ockrim ZK, Martinelli R, Futter CE, Grant MB, Fraser PA, Shima DT, Greenwood J, Turowski P.

Dev Cell. 2014 Sep 8;30(5):541-52. doi: 10.1016/j.devcel.2014.06.027. Epub 2014 Aug 28.

27.

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.

Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS, Shima DT.

Invest Ophthalmol Vis Sci. 2014 May 20;55(6):3709-19. doi: 10.1167/iovs.14-13989.

28.

A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome.

Anderson OA, Finkelstein A, Shima DT.

PLoS One. 2013 Jun 28;8(6):e67263. doi: 10.1371/journal.pone.0067263. Print 2013.

29.

Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J).

Ogawa H, Goto S, Matsuzaki M, Hiro S, Shima D; APPRAISE-J investigators.

Circ J. 2013;77(9):2341-8. Epub 2013 Jun 7.

30.

VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.

Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS.

Am J Pathol. 2013 Apr;182(4):1379-90. doi: 10.1016/j.ajpath.2012.12.032. Epub 2013 Feb 12.

31.

Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.

Hotta K, Nashimoto A, Yasumura E, Suzuki M, Azuma M, Iizumi Y, Shima D, Nabeshima R, Hiramoto M, Okada A, Sakata-Sogawa K, Tokunaga M, Ito T, Ando H, Sakamoto S, Kabe Y, Aizawa S, Imai T, Yamaguchi Y, Watanabe H, Handa H.

Mol Pharmacol. 2013 May;83(5):930-8. doi: 10.1124/mol.112.081935. Epub 2013 Feb 7.

PMID:
23393163
32.

Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.

Robbie SJ, Lundh von Leithner P, Ju M, Lange CA, King AG, Adamson P, Lee D, Sychterz C, Coffey P, Ng YS, Bainbridge JW, Shima DT.

Invest Ophthalmol Vis Sci. 2013 Feb 27;54(2):1490-500. doi: 10.1167/iovs.12-10169.

PMID:
23385800
33.

Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.

Tsujimoto M, Hatozaki D, Shima D, Yokota H, Furukubo T, Izumi S, Yamakawa T, Minegaki T, Nishiguchi K.

Ther Apher Dial. 2012 Dec;16(6):580-7. doi: 10.1111/j.1744-9987.2012.01100.x. Epub 2012 Aug 29.

PMID:
23190519
34.

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.

Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM, Kanthou C.

PLoS One. 2012;7(5):e35231. doi: 10.1371/journal.pone.0035231. Epub 2012 May 2.

35.

Forkhead box N4 (Foxn4) activates Dll4-Notch signaling to suppress photoreceptor cell fates of early retinal progenitors.

Luo H, Jin K, Xie Z, Qiu F, Li S, Zou M, Cai L, Hozumi K, Shima DT, Xiang M.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):E553-62. doi: 10.1073/pnas.1115767109. Epub 2012 Feb 8.

36.

Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.

Tsujimoto M, Higuchi K, Shima D, Yokota H, Furukubo T, Izumi S, Yamakawa T, Otagiri M, Hirata S, Takara K, Nishiguchi K.

J Pharm Pharmacol. 2010 Jan;62(1):133-8. doi: 10.1211/jpp.62.01.0015.

PMID:
20723009
37.

Delivery of anti-angiogenic molecular therapies for retinal disease.

Anderson OA, Bainbridge JW, Shima DT.

Drug Discov Today. 2010 Apr;15(7-8):272-82. doi: 10.1016/j.drudis.2010.02.004. Epub 2010 Feb 23. Review.

PMID:
20184967
38.

The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.

Krilleke D, Ng YS, Shima DT.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1201-6. doi: 10.1042/BST0371201.

PMID:
19909247
39.

Delta-like 4 is indispensable in thymic environment specific for T cell development.

Hozumi K, Mailhos C, Negishi N, Hirano K, Yahata T, Ando K, Zuklys S, Holländer GA, Shima DT, Habu S.

J Exp Med. 2008 Oct 27;205(11):2507-13. doi: 10.1084/jem.20080134. Epub 2008 Sep 29.

40.

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, Greco O, Harris S, Hill SA, Honess DJ, Ireson CR, Pettyjohn KL, Prise VE, Reyes-Aldasoro CC, Ruhrberg C, Shima DT, Kanthou C.

Cancer Res. 2008 Apr 1;68(7):2301-11. doi: 10.1158/0008-5472.CAN-07-2011.

41.

Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.

Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):662-70. doi: 10.1167/iovs.07-0195.

PMID:
18235012
42.

RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.

Mitchell TS, Bradley J, Robinson GS, Shima DT, Ng YS.

Angiogenesis. 2008;11(2):141-51. Epub 2007 Nov 25.

PMID:
18038251
43.

Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.

Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, Shima DT.

J Biol Chem. 2007 Sep 21;282(38):28045-56. Epub 2007 Jul 10.

44.

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT.

Am J Pathol. 2007 Jul;171(1):53-67.

45.

Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.

Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange N.

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1767-72.

PMID:
17389510
46.

Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8.

PMID:
17325165
47.

Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality.

Müller JM, Deinhardt K, Rosewell I, Warren G, Shima DT.

Biochem Biophys Res Commun. 2007 Mar 9;354(2):459-65. Epub 2007 Jan 8.

PMID:
17239345
48.

Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.

Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C.

Mol Vis. 2006 Oct 26;12:1243-9.

49.

An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis.

Ioannidou S, Deinhardt K, Miotla J, Bradley J, Cheung E, Samuelsson S, Ng YS, Shima DT.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16770-5. Epub 2006 Oct 30.

50.

Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT.

Mol Vis. 2006 May 23;12:532-80.

Supplemental Content

Support Center